Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Illumina (ILMN)

Illumina completes $350 million SomaLogic proteomics acquisition from Standard BioTools

Neutral Impact 4 of 5 m&a Written later

Illumina completed its acquisition of SomaLogic and related aptamer-based and functional proteomics assets from Standard BioTools on January 30, 2026, paying $350 million in cash at closing, subject to customary adjustments. The deal adds up to $75 million in potential milestone payments and royalties tied to product and service revenue, and Illumina said it funded the purchase with cash on hand. The filing does not give financial results for the acquired business, which Illumina said it will discuss on its February 5, 2026 earnings call.

Key points

  • Purchase price of $350 million in cash at closing, subject to customary adjustments
  • Up to $75 million in potential milestone payments to Standard BioTools, plus royalty streams
  • Transaction completed January 30, 2026; agreement dated June 22, 2025
  • Illumina will discuss the financial implications on its February 5, 2026 earnings call

The filing

CompanyIllumina (ILMN)
Form8-K, current report
Filed with the SECJan 30, 2026, 9:06 AM ET
Accession number0001110803-26-000014

Items reported: 2.01 Acquisition or Disposition Completed8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:30 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 30, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.